The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC).
S. Viswanathan
Stock Ownership - Abbott Laboratories
R. Wesolowski
No relevant relationships to disclose
R. M. Layman
No relevant relationships to disclose
G. Alejandra
No relevant relationships to disclose
B. Miller
No relevant relationships to disclose
J. J. Chalmers
No relevant relationships to disclose
S. Bejastani
No relevant relationships to disclose
W. Zhao
No relevant relationships to disclose
G. Pierluigu
No relevant relationships to disclose
J. Cotrill
No relevant relationships to disclose
M. A. Phelps
No relevant relationships to disclose
L. J. Schaaf
No relevant relationships to disclose
S. M. Geyer
No relevant relationships to disclose
N. Hall
No relevant relationships to disclose
M. V. Knopp
No relevant relationships to disclose
C. L. Shapiro
No relevant relationships to disclose
M. A. Villalona-Calero
No relevant relationships to disclose
A. Chen
No relevant relationships to disclose
M. R. Grever
No relevant relationships to disclose
B. Ramaswamy
No relevant relationships to disclose